Orion Corporation

Saila Antila

Lasse Lehtonen

Arto Olavi Urtti

Ilkka Larma

Jouni Hirvonen

Maarit Bäckman

Iikka Larma

The invention relates to peroral pharmaceutical compositions which release levosimendan in a controlled fashion with reduced occurrence of undesired effects. Levosimendan, or (&#x2212;)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile, is useful in the treatment of congestive heart failure.

Controlled release peroral compositions of levosimendan

A composition for oral administration comprising a substantially pure crystalline polymorphic form (I) of levosimendan as an active ingredient together with a pharmaceutically acceptable carrier is described. Polymorphic form (I) of levosimendan is rapidly absorbed from the gastrointestinal tract and is useful in the treatment of congestive heart disease.

Oral compositions of levosimendan

Transdermal administration of levosimenden or (&minus;)-&lsqb;&lsqb;4-(1,4,5,6-tetahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono&rsqb;propanedinitrile or a pharmaceutically acceptable salt thereof is disclosed. Transdermal preparations of levosimenden can be in the form of e.g. ointment, emulsion, lotion, solution, gel, cream, patch or transdermal delivery device including iontophoretic device.

Growing community of inventors

Helsinki, Finland

Saila Antila